MAPK3 and ovarian carcinoma: The data indicate the biphasic nature of ERK1/2 and its complex role in the cells’ response to cisplatin, which should be considered during preparation of pre-clinical trials for pharmacological inhibitors of these kinases as supportive compounds for ovarian cancer treatment.